Biotech co-founder set­tles ma­jor re­search mis­con­duct al­le­ga­tions with HHS

In one life, Vi­ravuth Yin is an in­ter­na­tion­al­ly-rec­og­nized ex­pert in re­gen­er­a­tive bi­ol­o­gy who pi­o­neered the use of the ze­brafish as a drug screen­ing plat­form, dis­cov­ered a po­ten­tial new re­gen­er­a­tive heart drug and spun that dis­cov­ery in­to a new biotech start­up known as No­vo Bio­sciences, where he now serves as co-founder and CSO.

But in an­oth­er life, a life that he’s try­ing to move past with an HHS set­tle­ment on Wednes­day, Yin is al­leged to have com­mit­ted ma­jor re­search mis­con­duct, in­clud­ing “know­ing­ly, in­ten­tion­al­ly, and/or reck­less­ly fal­si­fy­ing and/or fab­ri­cat­ing da­ta” on three pub­lished pa­pers and two man­u­scripts. Those three pub­lished pa­pers, two of which were pub­lished in iScience, will now be re­tract­ed, at Yin’s re­quest, ac­cord­ing to the set­tle­ment.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN